

World Journal of *Gastrointestinal Oncology*

World J Gastrointest Oncol 2023 September 15; 15(9): 1505-1674



Contents

Monthly Volume 15 Number 9 September 15, 2023

REVIEW

- 1505** Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways
Bararia A, Das A, Mitra S, Banerjee S, Chatterjee A, Sikdar N

MINIREVIEWS

- 1520** Metastasis-associated lung adenocarcinoma transcript 1 molecular mechanisms in gastric cancer progression
Batista DMO, da Silva JMC, Gigeck CO, Smith MAC, de Assumpção PP, Calcagno DQ

ORIGINAL ARTICLE

Basic Study

- 1531** RNA-binding protein CPSF6 regulates IBSP to affect pyroptosis in gastric cancer
Wang XJ, Liu Y, Ke B, Zhang L, Liang H
- 1544** Osteopontin promotes gastric cancer progression *via* phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway
Qin YC, Yan X, Yuan XL, Yu WW, Qu FJ
- 1556** MicroRNA-363-3p inhibits colorectal cancer progression by targeting interferon-induced transmembrane protein 1
Wang Y, Bai SK, Zhang T, Liao CG

Clinical and Translational Research

- 1567** Cellular senescence throws new insights into patient classification and pharmacological interventions for clinical management of hepatocellular carcinoma
Wang HH, Chen WL, Cui YY, Gong HH, Li H

Case Control Study

- 1595** Comparison of ethanol-soaked gelatin sponge and microspheres for hepatic arterioportal fistulas embolization in hepatic cellular carcinoma
Yuan GS, Zhang LL, Chen ZT, Zhang CJ, Tian SH, Gong MX, Wang P, Guo L, Shao N, Liu B

Retrospective Cohort Study

- 1605** Incorporation of perigastric tumor deposits into the TNM staging system for primary gastric cancer
Li Y, Li S, Liu L, Zhang LY, Wu D, Xie TY, Wang XX
- 1616** Multidisciplinary discussion and management of synchronous colorectal liver metastases: A single center study in China
Li H, Gu GL, Li SY, Yan Y, Hu SD, Fu Z, Du XH

Retrospective Study

- 1626** Hemoglobin, albumin, lymphocyte, and platelet score as a predictor of prognosis in metastatic gastric cancer

Duzkopru Y, Kocanoglu A, Dogan O, Sahinli H, Cilbir E, Altinbas M

- 1636** Efficacy of multi-slice spiral computed tomography in evaluating gastric cancer recurrence after endoscopic submucosal dissection

Yin JJ, Hu X, Hu S, Sheng GH

- 1644** Factors associated with heterochronic gastric cancer development post-endoscopic mucosal dissection in early gastric cancer patients

Xie B, Xia Y, Wang X, Xiong Y, Chen SB, Zhang J, He WW

Observational Study

- 1653** Utilization of access to colorectal cancer screening modalities in low-income populations after medicaid expansion

Fletcher G, Culpepper-Morgan J, Genao A, Alatevi E

- 1662** Fibrinogen-to-albumin ratio predicts overall survival of hepatocellular carcinoma

Sun H, Ma J, Lu J, Yao ZH, Ran HL, Zhou H, Yuan ZQ, Huang YC, Xiao YY

CORRECTION

- 1673** Correction to “Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells”

Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX

ABOUT COVER

Editorial Board Member of *World Journal of Gastrointestinal Oncology*, Qiang Lin, MD, PhD, Professor, Department of Oncology, North China Petroleum Bureau General Hospital, Hebei Medical University, Renqiu 062552, Hebei Province, China. billhappy001@163.com

AIMS AND SCOPE

The primary aim of *World Journal of Gastrointestinal Oncology* (WJGO, *World J Gastrointest Oncol*) is to provide scholars and readers from various fields of gastrointestinal oncology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJGO mainly publishes articles reporting research results and findings obtained in the field of gastrointestinal oncology and covering a wide range of topics including liver cell adenoma, gastric neoplasms, appendiceal neoplasms, biliary tract neoplasms, hepatocellular carcinoma, pancreatic carcinoma, cecal neoplasms, colonic neoplasms, colorectal neoplasms, duodenal neoplasms, esophageal neoplasms, gallbladder neoplasms, *etc.*

INDEXING/ABSTRACTING

The WJGO is now abstracted and indexed in PubMed, PubMed Central, Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2023 edition of Journal Citation Reports® cites the 2022 impact factor (IF) for WJGO as 3.0; IF without journal self cites: 2.9; 5-year IF: 3.0; Journal Citation Indicator: 0.49; Ranking: 157 among 241 journals in oncology; Quartile category: Q3; Ranking: 58 among 93 journals in gastroenterology and hepatology; and Quartile category: Q3. The WJGO's CiteScore for 2022 is 4.1 and Scopus CiteScore rank 2022: Gastroenterology is 71/149; Oncology is 197/366.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Xiang-Di Zhang; Production Department Director: Xiang Li; Editorial Office Director: Jia-Ru Fan.

NAME OF JOURNAL

World Journal of Gastrointestinal Oncology

ISSN

ISSN 1948-5204 (online)

LAUNCH DATE

February 15, 2009

FREQUENCY

Monthly

EDITORS-IN-CHIEF

Monjur Ahmed, Florin Burada

EDITORIAL BOARD MEMBERS

<https://www.wjgnet.com/1948-5204/editorialboard.htm>

PUBLICATION DATE

September 15, 2023

COPYRIGHT

© 2023 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

<https://www.wjgnet.com/bpg/gerinfo/204>

GUIDELINES FOR ETHICS DOCUMENTS

<https://www.wjgnet.com/bpg/GerInfo/287>

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

<https://www.wjgnet.com/bpg/gerinfo/240>

PUBLICATION ETHICS

<https://www.wjgnet.com/bpg/GerInfo/288>

PUBLICATION MISCONDUCT

<https://www.wjgnet.com/bpg/gerinfo/208>

ARTICLE PROCESSING CHARGE

<https://www.wjgnet.com/bpg/gerinfo/242>

STEPS FOR SUBMITTING MANUSCRIPTS

<https://www.wjgnet.com/bpg/GerInfo/239>

ONLINE SUBMISSION

<https://www.f6publishing.com>



Correction to “Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells”

Chuan-Hong Li, Zhang-Ming Chen, Pei-Feng Chen, Lei Meng, Wan-Nian Sui, Song-Cheng Ying, A-Man Xu, Wen-Xiu Han

Specialty type: Oncology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): A

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Senchukova M, Russia; Sheykhasan M, Iran; Yildiz K, Turkey

Received: May 16, 2023

Peer-review started: May 16, 2023

First decision: June 26, 2023

Revised: July 7, 2023

Accepted: July 31, 2023

Article in press: July 31, 2023

Published online: September 15, 2023



Chuan-Hong Li, Zhang-Ming Chen, Pei-Feng Chen, Lei Meng, Wan-Nian Sui, A-Man Xu, Wen-Xiu Han, Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China

Song-Cheng Ying, Department of Immunology, College of Basic Medicine, Anhui Medical University, Hefei 230022, Anhui Province, China

Corresponding author: Wen-Xiu Han, MD, PhD, Professor, Department of General Surgery, First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Avenue, Shushan District, Hefei 230022, Anhui Province, China. hwxbh@126.com

Abstract

Correction to “Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells”. In this article, we found the following error in Figure 3A: The panel image “24 h, sh-RNA1” in the AGS cells wound healing assay was incorrectly inserted during the preparation of the submission; the correct figure is provided in this correction.

Key Words: Correction; Gastric cancer; Interleukin-34; Proliferation; Epithelial-mesenchymal transition; Metastasis

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: The aim of this manuscript is to correct the image in Figure 3A of “Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX. Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells. *World J Gastrointest Oncol* 2022; 14: 1968-1980 [PMID: 36310707 DOI: 10.4251/wjgo.v14.i10.1968].

Citation: Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX. Correction to “Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells”. *World J Gastrointest Oncol* 2023; 15(9): 1673-1674

URL: <https://www.wjgnet.com/1948-5204/full/v15/i9/1673.htm>

DOI: <https://dx.doi.org/10.4251/wjgo.v15.i9.1673>

TO THE EDITOR

Correction to: Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX. Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells. *World J Gastrointest Oncol* 2022; 14: 1968-1980 [PMID: 36310707 DOI: 10.4251/wjgo.v14.i10.1968]. We identified the following error in Figure 3A of the original version of the published article: The image relative to "24 h, sh-RNA1" in the AGS cell wound healing assay was inserted incorrectly during the preparation of the submission. The correct Figure is provided in this correction (Figure 1). This correction will have no influence on the interpretation of the results and conclusion in this study. We apologize for any inconvenience this may have caused.




Figure 1 Interleukin-34 regulates the migration and invasiveness of AGS cells. A and B: Wound-healing assay revealed that downregulation of endogenous interleukin-34 significantly reduced the migration rate. Data derived from three independent experiments performed in triplicate and expressed as mean \pm SD, and $^*P < 0.05$ was considered statistically significant.

FOOTNOTES

Author contributions: Li CH wrote the manuscript; All authors approved the submitted version.

Conflict-of-interest statement: There is no conflict of interest in this study.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Chuan-Hong Li 0000-0002-3945-972X; Zhang-Ming Chen 0000-0002-4830-0745; Pei-Feng Chen 0000-0003-2843-425X; Lei Meng 0000-0002-1089-1228; Wan-Nian Sui 0000-0002-4337-5238; Song-Cheng Ying 0000-0002-3446-4482; A-Man Xu 0000-0002-7171-5295; Wen-Xiu Han 0000-0002-5335-9645.

S-Editor: Fan JR

L-Editor: A

P-Editor: Xu ZH

REFERENCES

- Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX. Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells. *World J Gastrointest Oncol* 2022; 14: 1968-1980 [PMID: 36310707 DOI: 10.4251/wjgo.v14.i10.1968]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

